Kane Biotech (CVE:KNE) Hits New 1-Year Low – Should You Sell?

Kane Biotech Inc. (CVE:KNE) shares hit a new 52-week low on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 279000 shares trading hands. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The stock has a market capitalization of C$5.02 million, a P/E ratio of -0.38 and a beta of 0.60. The company has a debt-to-equity ratio of -289.57, a quick ratio of 0.39 and a current ratio of 0.90. The firm has a fifty day moving average price of C$0.04 and a two-hundred day moving average price of C$0.04.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.